Neil Kumar, BridgeBio

Bridge­Bio spins gold out of an Alex­ion castoff, scor­ing an FDA ap­proval in rare me­tab­o­lism dis­or­der

Now part of the fold at As­traZeneca, rare dis­ease spe­cial­ist Alex­ion doesn’t miss of­ten when it comes to tak­ing meds across the fin­ish line. But in one spe­cial case, Bridge­Bio took an Alex­ion castoff on board — and now it’s turned the drug in­to a win­ner.

The FDA ap­proved Bridge­Bio’s Nuli­bry (fos­denopterin), once known as ALXN1101, on Fri­day to treat molyb­de­num co­fac­tor de­fi­cien­cy type A, an au­to­so­mal re­ces­sive, in­born er­ror of me­tab­o­lism caused by mu­ta­tions in the molyb­de­num co­fac­tor syn­the­sis 1 gene (MOCS1).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.